Skip to content
Erudio Health
menu
Clinical trial · no report yet · Phase 3

CARTITUDE-5

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

  • NCT04923893 ↗
  • Active not recruiting
  • Janssen Research & Development, LLC
  • 88 commentary sources found
  • Deep

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Commentary we found

Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.

ChannelFound
YouTube42
X threads31
Podcasts15

The trial

ClinicalTrials.gov
Official title
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Phase
Phase 3
Status
Active not recruiting
Conditions
Multiple Myeloma
Interventions
Bortezomib; Dexamethasone; Lenalidomide; Cilta-cel; Cyclophosphamide; Fludarabine
Arms
  • Arm A: VRd+Rd (Standard Therapy) · Experimental
  • Arm B: VRd+Ciltacabtagene Autoleucel (Cilta-cel) · Experimental
Enrollment
743
Primary outcomes
  • Progression Free Survival (PFS)
Sponsor
Janssen Research & Development, LLC
Start
Aug 19, 2021
Primary completion
Feb 14, 2029 (estimated)
Results posted
No
Registry record
NCT04923893 · updated Sep 25, 2026